Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter.
Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 95
The Genomic Revolution: Implications for Treatment and Control of Infectious Disease - Working Group Summaries
Appendixes
OCR for page 96
The Genomic Revolution: Implications for Treatment and Control of Infectious Disease - Working Group Summaries
This page intentionally left blank.
OCR for page 97
The Genomic Revolution: Implications for Treatment and Control of Infectious Disease - Working Group Summaries
The 3rd Annual National Academies Keck Futures Initiative Conference
The Genomic Revolution:
Implications for Treatment and Control of Infectious Disease
Arnold and Mabel Beckman Center, Irvine, California
November 10-13, 2005
AGENDA
Wednesday, November 9 (Hyatt Regency Newport Beach)
6:00–10:00 p.m.
Welcome Reception / Registration – Garden Room 1 & Garden
Thursday, November 10 (Arnold and Mabel Beckman Center of the National Academies)
7:45 and 8:15 a.m.
Bus pick-up from the Hyatt Regency Newport
Beach to the Beckman Center
8:00 a.m.
Registration (Outside Auditorium)
8:00–9:00 a.m.
Breakfast (Dining Room)
9:00–9:30 a.m.
Welcome and Opening Remarks (Auditorium)
Wm. A. Wulf, President, National Academy of Engineering
Harvey V. Fineberg, President, Institute of Medicine
Richard N. Foster, Board Member, W.M. Keck Foundation
Robert Waterston, Chair, Genomics Steering Committee
OCR for page 98
The Genomic Revolution: Implications for Treatment and Control of Infectious Disease - Working Group Summaries
9:30–10:30 a.m.
Overview “Tutorial” Sessions
Genomics, Structural Biology, and Rational Vaccine Design
Gary J. Nabel
Director of the Vaccine Research Center
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Diversity of Human Microbial Pathogens and Commensals / Host-Pathogen Interaction (Part I)
David Relman
Associate Professor of Microbiology & Immunology and of Medicine Stanford University
Chief, Infectious Diseases Section
Veterans Administration Palo Alto Health Care System
Question and Answer section for these two presentations will take place at 11:30
10:30–11:00 a.m.
Break (Atrium)
11:00 a.m. – 12:15 p.m.
Overview “Tutorial” Sessions / Q&A
Diversity of Human Microbial Pathogens and Commensals / Host-Pathogen Interaction (Part II)
David Relman
11:30–12:15 Q&A – Gary Nabel,
David Relman, and Claire Fraser
12:15–1:30 p.m.
Lunch (Dining Room)
OCR for page 99
The Genomic Revolution: Implications for Treatment and Control of Infectious Disease - Working Group Summaries
1:30–3:00 p.m.
Overview “Tutorial” Sessions / Q&A
Team Science
Mary E. Lidstrom
Vice Provost of Research
Professor in Chemical Engineering and Microbiology
Frank Jungers Chair of Engineering
University of Washington
Team Science: The Microscale Life Sciences Center (MLSC)
Deirdre Meldrum
Director, NIH CEGS Microscale Life Sciences Center and the UW Genomation Laboratory
Professor of Electrical Engineering
University of Washington
2:30–3:00 Q&A
3:00–3:30 p.m.
Task to Working Group
3:30–4:00 p.m.
Break (Atrium / Palm Court 2 / Bay View 2)
4:00–6:00 p.m.
Working Group Session 1 (Locations throughout Beckman Center)
2.
Technology to improve rapid response.
Bay View II – 2nd floor
3.
Develop an inexpensive diagnostic test.
Laguna – 2nd floor
5.
Spend $100 million to prevent the next pandemic flu.
Emerald Bay – 2nd floor
6.
Can genomics facilitate vaccine development?
Irvine Cove – 2nd floor
9.
Develop a device to detect and identify pathogens.
Board Room – 1st floor
OCR for page 100
The Genomic Revolution: Implications for Treatment and Control of Infectious Disease - Working Group Summaries
10.
Shared pathways of attack for prevention.
Harbour – 2nd floor
11-1.
Role of public health in integrating genomics.
Balboa – 1st floor
11-2.
Role of public health in integrating genomics.
Newport – 1st floor
12.
Sequence an individual’s genome for under $1,000.
Crystal Cove – 1st floor
14-1.
Natural variation in disease resistance.
Lido – 2nd floor
14-2.
Natural variation in disease resistance.
Back Bay – 2nd floor
6:00–7:00 p.m.
Reception / Networking
7:00–9:00 p.m.
Dinner and Communication Awards Presentation (Atrium)
9:00 p.m.
Buses depart Beckman Center for Hyatt Regency Newport Beach
9:00–11:00 p.m.
Informal Discussions / Hospitality Room
Hyatt Regency Newport Beach – Garden Room 1 and Garden
Friday, November 11 (Beckman Center)
7:15 and 7:45 a.m.
Bus pick-up from the Hyatt Regency Newport
Beach to the Beckman Center
7:30–8:30 a.m.
Breakfast (Dining Room)
8:30–10:45 a.m.
Overview “Tutorial” Sessions / Q&A (Auditorium)
OCR for page 101
The Genomic Revolution: Implications for Treatment and Control of Infectious Disease - Working Group Summaries
Some Roles of Computation in Molecular Biology
Michael Waterman
University Professor
Professor of Biological Sciences, Mathematics, and Computer Science
University of Southern California
Human Genetic Variation
Leonid Kruglyak
Professor of Ecology and Evolutionary Biology and the Lewis-Sigler Institute for Integrative Genomics
Princeton University
Dual Meaning of Dual Use
Robert Cook-Deegan
Director, Center for Genome Ethics, Law, and Policy
Institute for Genome Sciences and Policy
Duke University
10:00–10:45 Q&A
10:45–11:15 a.m.
Break (Atrium) / Friday Poster Set-up
11:15 a.m. – 12:45 p.m.
Overview “Tutorial” Sessions / Q&A
Issues from Developing Countries: What are their needs? What are their unique delivery and implementation issues (access, cost, power requirements, transportability, etc.)?
Austin Demby
Senior Staff Fellow
Global AIDS Program
Centers for Disease Control and Prevention
OCR for page 102
The Genomic Revolution: Implications for Treatment and Control of Infectious Disease - Working Group Summaries
Genetic Analysis of Innate Immune Sensing
Bruce Beutler
Professor
Department of Immunology
Scripps Research Institute
12:15–12:45 Q&A
12:45–2:00 p.m.
Lunch (Friday session posters available for previewing)
2:00–3:45 p.m.
Working Group Session 2 (Same meeting places as session 1)
(3:00–3:45—Coffee and refreshments will be available in the Atrium, Palm Court 2, and Bay View 2)
3:45–5:00 p.m.
Working Group Report Outs (Each group gives a 5 minute debrief) (Aud.)
5:00–6:30 p.m.
Friday Poster Session
5:00–5:45 p.m.
Odd numbered posters are attended
5:45–6:30 p.m.
Even numbered posters are attended
(Refreshments will be served Atrium)
6:30 p.m.
Buses depart Beckman Center for Hyatt Regency Newport Beach
7:00–9:00 p.m.
Buffet Dinner – Hyatt Regency Newport Beach – Terrace Room
9:00–11:00 p.m.
Informal Discussions / Hospitality Room
Hyatt Regency Newport Beach – Garden Room 1 and Garden
OCR for page 103
The Genomic Revolution: Implications for Treatment and Control of Infectious Disease - Working Group Summaries
Saturday, November 12 (Beckman Center)
7:45 and 8:15 a.m.
Bus pick-up from the Hyatt Regency Newport
Beach to the Beckman Center
8:00–9:00 a.m.
Breakfast (Dining Room)
9:00–10:30 a.m.
Overview “Tutorial” Sessions / Q&A (Auditorium)
Human Genome Sequencing at $5,000 a Pop
Robert H. Waterston
Head, Department of Genome Sciences
William H. Gates III Chair of Biomedical Sciences
University of Washington School of Medicine
Microsystems
Todd Thorsen
Assistant Professor of Mechanical Engineering
Massachusetts Institute of Technology
10:00–10:30 Q&A
10:30–11:00 a.m.
Break (Atrium) / Saturday Poster Set-up
11:00 a.m. – 1:00 p.m.
Working Group Session 3 (Same meeting places as session 1)
1:00–2:00 p.m.
Lunch (Saturday session posters available for previewing)
2:00–3:30 p.m.
Saturday Poster Session
2:00–2:45 p.m.
Odd numbered posters are attended
2:45–3:30 p.m.
Even numbered posters are attended
(3:00–4:00—Coffee and refreshments will be available in the Huntington Room, Palm Court 2, and Bay View 2)
OCR for page 104
The Genomic Revolution: Implications for Treatment and Control of Infectious Disease - Working Group Summaries
3:30–5:30 p.m.
Working Group Session 4 (Same meeting places as session 1)
5:30–6:30 p.m.
Networking / Reception
6:30 - 8:00 p.m.
Dinner (Atrium)
8:00 p.m.
Buses depart Beckman Center for Hyatt Regency Newport Beach
9:00–11:00 p.m.
Informal Discussions / Hospitality Room
Hyatt Regency Newport Beach – Garden Room 1 and Garden
Sunday, November 13 (Beckman Center)
7:15 and 7:45 a.m.
Bus pick-up from the Hyatt Regency Newport
Beach to the Beckman Center
7:30–8:30 a.m.
Breakfast (Dining Room)
8:30–10:15 a.m.
Working Group Report-Outs (Auditorium) (15 minutes per group)
10:15–10:45 a.m.
Break (Atrium)
10:45 a.m. – 12:00 p.m.
Working Group Report-Outs – continued (Auditorium)
12:00–1:00 p.m.
Lunch
12:00 and 1:00 p.m.
Buses depart for Hyatt Regency Newport Beach and John Wayne Airport
OCR for page 105
The Genomic Revolution: Implications for Treatment and Control of Infectious Disease - Working Group Summaries
THE GENOMIC REVOLUTION: IMPLICATIONS FOR TREATMENT AND CONTROL OF INFECTIOUS DISEASE WORKING GROUP TOPICS
TECHNOLOGY
Design a point-of-care diagnostics for rapid detection of viral and bacterial pathogens. (not running)
Identify what technological advances in the fields of science and engineering need to be developed (either new technology or novel integration of existing technologies) to improve rapid response to new or emerging diseases? For example, can carefully reengineered viruses or bacteria become the next generation of therapeutic agents? How can computational biology better integrate the vast amounts of genomic knowledge to assist these efforts?
Develop an inexpensive (and cost-effective) diagnostic test (infection, genotype) that could be deployed in countries with little scientific research infrastructure. How can nanotechnology and new rapid diagnostic methods for other targets be adapted to diagnose malaria species, drug-resistance mutations, and vaccine-resistance polymorphisms in malaria-endemic countries?
Can genetically modified organisms be used to control disease? (not running)
VACCINES / GENOMIC ANALYSIS AND SYNTHESIS
How would you spend $100 million over the next five years to prevent the next pandemic flu? What would be the research strategy to utilize fully the genomic sequences of the hosts and pathogens to accelerate the development of therapeutics and vaccines for its prevention and control?
How can genomics facilitate vaccine development? Would efficient methods of synthesis of genomes help? Can genomics help to improve the assessment of efficacy of vaccines? What are the safety concerns?
OCR for page 106
The Genomic Revolution: Implications for Treatment and Control of Infectious Disease - Working Group Summaries
How can genomic analysis of immune evasion strategies facilitate vaccination against HIV? (not running)
How can genomic analysis of immune evasion strategies facilitate vaccination against malaria? (not running)
DIAGNOSIS
Develop a device to rapidly and sensitively detect and identify pathogens in an environment/population, spread either naturally or through deliberate acts. Can genomics help differentiate between natural and deliberate disease outbreak and provide evidence for attribution? Do we know what defines—both genotypically and phenotypically—a pathogen vs. a nonpathogenic invader? If not, how can we determine this?
Are there shared pathways of attack that might provide new avenues of prevention? How can we find them? Once identified, what methods can be developed to stop them?
Explore the emerging role of public health in integrating genomics in surveillance, outbreak investigations, and control and prevention of infectious diseases. (two sections will be running due to high interest in this topic)
NATURAL VARIATION
What will it take to sequence an individual person’s genome for under $1,000 in ten years?
Can evolutionary models of the emergence of resistance in a pathogen combined with combinatorial treatment schemes be used to develop a strategy to hold the pathogen in check? (not running)
How can we use natural variation in disease resistance to understand host-pathogen interactions and devise new therapies? (two sections will be running due to high interest in this topic)
Representative terms from entire chapter:
regency newport
